NASDAQ:ONCY - CA6823108759 - Common Stock
The current stock price of ONCY is 1.11 USD. In the past month the price increased by 22.11%. In the past year, price increased by 21.09%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.1 | 376.10B | ||
AMGN | AMGEN INC | 12.89 | 151.36B | ||
GILD | GILEAD SCIENCES INC | 14.56 | 139.79B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.38 | 101.53B | ||
REGN | REGENERON PHARMACEUTICALS | 12.44 | 60.20B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.58B | ||
ARGX | ARGENX SE - ADR | 78.94 | 44.78B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.46 | 38.06B | ||
INSM | INSMED INC | N/A | 29.93B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
NTRA | NATERA INC | N/A | 22.91B | ||
BIIB | BIOGEN INC | 8.64 | 20.27B |
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2000-06-01. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The company acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The firm is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
ONCOLYTICS BIOTECH INC
804, 322 - 11 Avenue Sw, Calgary Alberta Canada T2n 1X7
Calgary ALBERTA T2N 1X7 CA
CEO: Matthew C. Coffey
Employees: 29
Phone: 14036707377
The current stock price of ONCY is 1.11 USD. The price decreased by -4.31% in the last trading session.
The exchange symbol of ONCOLYTICS BIOTECH INC is ONCY and it is listed on the Nasdaq exchange.
ONCY stock is listed on the Nasdaq exchange.
8 analysts have analysed ONCY and the average price target is 3.32 USD. This implies a price increase of 199.04% is expected in the next year compared to the current price of 1.11. Check the ONCOLYTICS BIOTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ONCOLYTICS BIOTECH INC (ONCY) has a market capitalization of 98.59M USD. This makes ONCY a Micro Cap stock.
ONCOLYTICS BIOTECH INC (ONCY) currently has 29 employees.
ONCOLYTICS BIOTECH INC (ONCY) has a support level at 1.07 and a resistance level at 1.26. Check the full technical report for a detailed analysis of ONCY support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ONCY does not pay a dividend.
ONCOLYTICS BIOTECH INC (ONCY) will report earnings on 2025-11-10, after the market close.
ONCOLYTICS BIOTECH INC (ONCY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.27).
The outstanding short interest for ONCOLYTICS BIOTECH INC (ONCY) is 2.91% of its float. Check the ownership tab for more information on the ONCY short interest.
ChartMill assigns a technical rating of 9 / 10 to ONCY. When comparing the yearly performance of all stocks, ONCY is one of the better performing stocks in the market, outperforming 97.35% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to ONCY. ONCY may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ONCY reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS increased by 2.63% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -152.26% | ||
ROE | -499.46% | ||
Debt/Equity | 0.1 |
8 analysts have analysed ONCY and the average price target is 3.32 USD. This implies a price increase of 199.04% is expected in the next year compared to the current price of 1.11.